Otezla(apremilast)
Otezla 14-Day 10/20/30 Starter Pack
NO BOXED WARNING
Dosage & Administration
Get Your Patient on Otezla
See your patient's specific prior authorization requirements including coverage restrictions and step therapies
Or select your Insurance from the list below:
Otezla Prescribing Information
Request Otezla Samples
Learn More
Is my patient eligible for Otezla samples?
- Your rep will communicate with you how to receive samples, when you can receive samples, the amount and more.
How do I find out who my Otezla rep is?
- Not sure who your local Otezla pharma rep is? Reach out to Celgene Corporation and they can help you identify your rep.
Otezla Prior Authorization Resources
Most recent state uniform prior authorization forms
Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form
Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form
Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form
Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form
Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form
Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form
Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form
Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form
Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form
Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form
Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form
Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form
Otezla Preferred Pharmacy
Otezla Financial Assistance Options
Copay savings program
Learn More
Overview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Otezla PubMed™ News
Otezla Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Otezla Patient Roadmap (Getting Your Otezla Prescription)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
About Otezla: Oral Ulcers in Bechet's Disease
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Otezla FAQs
Yes, there is a pregnancy exposure registry for OTEZLA that monitors pregnancy outcomes in women exposed to OTEZLA during pregnancy. For more information about the registry or to report a pregnancy while on OTEZLA, contact 1-877-311-8972 or visit https://mothertobaby.org/ongoing-study/otezla/.
Available pharmacovigilance data with OTEZLA use in pregnant women have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, but these data are extremely limited. Based on findings from animal reproduction studies, OTEZLA may increase the risk for fetal loss. The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Pregnant women should consult with their healthcare provider and consider pregnancy planning and prevention.
In embryo-fetal development studies, pregnant cynomolgus monkeys administered apremilast (OTEZLA) during organogenesis resulted in dose-related increases in abortion/embryo-fetal death at doses approximately 2.1-times the maximum recommended human therapeutic dose (MRHD) and greater. No abortifacient effects were observed at a dose approximately 1.4-times the MRHD. No teratogenic effects were observed in mice administered apremilast during organogenesis up to exposures 4.0-times the MRHD. Apremilast distributed across the placenta into the fetal compartment in mice and monkeys. Pregnant women should consult with their healthcare provider and consider pregnancy planning and prevention.
There are no data on the presence of apremilast in human milk. However, apremilast was detected in the milk of lactating mice. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OTEZLA and any potential adverse effects on the breastfed infant from OTEZLA or from the underlying maternal condition. Women should consult with their healthcare provider.
No, the safety and effectiveness of OTEZLA in pediatric patients less than 18 years of age have not been established.
According to clinical trials, there were no overall differences in the safety profile of geriatric patients ≥ 65 years of age and younger adult patients < 65 years of age. However, because patients 65 years of age or older may be at a higher risk of complications such as volume depletion or hypotension from severe diarrhea, nausea, or vomiting, monitor geriatric patients closely for such complications.
While no dosage adjustment is needed in patients with mild or moderate renal impairment, the dosage of OTEZLA should be reduced to 30 mg once daily in patients with severe renal impairment.
No, dosage adjustment is not necessary for OTEZLA in patients with moderate or severe hepatic impairment.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available